Business
AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Administration for market registration. In addition, the vaccine has obtained the corresponding product production license. Currently, there are no serum-free rabies vaccines approved for sale in the global market, and this product is expected to bec
About this update from Aim Vaccine Co., Ltd. Class H
[{"type":"text","content":"HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Administration for market registration. In addition, the vaccine has obtained the corresponding product production license. Currently, there are no serum-free rabies vaccines approved for sale in the global market, and this product is expected to become the first of its kind to launch.","length":591,"tagName":"p"},{"type":"text","content":"AIM Vaccine is rapidly advancing the market launch process for its iterative major vaccine products, confirming the optimistic forecasts made by investors. As noted in a research report published by Fosun International Securities on April 3, the operational improvements at AIM Vaccine have been validated, its innovative pipeline is ready to launch, and there is significant potential for valuation recovery. With the upcoming launches of three major new products, including the serum-free iterative rabies vaccine in the next 1-2 years, the company's revenue is expected to accelerate, and profitability is projected to improve significantly, potentially achieving breakeven and quickly entering a profit period after 2025. The target price for the company is maintained at HKD 11.22, with a "Buy" rating.","length":821,"tagName":"p"},{"type":"text","content":"According to the research report from Fosun International Securities, AIM's serum-free rabies vaccine well represents the direction of technological upgrades in rabies vaccines. The production process does not use animal serum, significantly increasing safety and reducing allergy risks, with excellent efficacy and safety indicators shown in Phase III clinical trial results.","length":380,"tagName":"p"},{"type":"text","content":"The serum-free iterative rabies vaccine is recognized as a high-value product in the industry. The report from Fosun International Securities points out that, based on solidifying its market share in Vero cell vaccines, AIM's serum-free iterative rabies vaccine and its iterative high-yield diploid cell (HDC) vaccine represent significant technological upgrades and value enhancement capabilities. The HDC...